Table 1 Studies reporting PAI-1 antigen levels (ng/mL) and major adverse cardiovascular events and restenosis

Sane et al. [50]

Cohort

24

Fibrinolytics

58

24

n/a

n/a

n/a

53

Cortellaro et al. [51]

Case-Control

24

Subgroups Combined

0.7

13

17

n/a

20

0 5

Brannstrom et al. [52]

Cohort

46

Anticoagulant

15.1

38

n/a

n/a

n/a

11.8

Juhan-Vague et al. [53]

Cohort

24

MI

8 2

40

66

n/a

n/a

8.9

Nordt et al. [54]

Cohort

12

Fibrinolytics

14.3

n/a

n/a

5

n/a

15.4

Alaigh et al. [55]

Cohort

6

Elective PCI

11.06

n/a

n/a

28

n/a

13.85

Moss et al. [56]

Cohort

26

MI

18

25

56

n/a

n/a

28

Redondo et al. [57]

Cohort

24

MI

22.28

2

5

30

n/a

21.02

Fornitz et al. [58]

Cohort

6

Elective PCI

26.6

n/a

n/a

7

n/a

27

Bogaty et al. [59]

Case-Control

48

MI

19.04

n/a

8

n/a

n/a

16.24

Ganti et al. [60]

Cohort

n/a

MI

16.38

4

n/a

n/a

n/a

21.95

Lip et al. [61]

Cohort

12

Stroke

30.7

27

n/a

n/a

n/a

23.3

Inoue et al. [62]

Cohort

6

MI

4

n/a

n/a

24

n/a

4

Christ et al. [20]

Cohort

6

Elective PCI

0.7

n/a

n/a

25

n/a

2.1

Robinson et al. [63]

Cohort

5 to 51

Coronary Heart Disease

17.9

2

2

n/a

2

25.6

Katsaros et al. [24]

Cohort

6 to 8

Elective PCI

8.05

n/a

n/a

12

n/a

18.76

Thogersen et al. [64]

Case-Control

n/a

Healthy

16.79

n/a

50

n/a

n/a

15.75

Akkus et al. [65]

Cohort

12

Cardiogenic Shock

97.26

33

n/a

n/a

n/a

54.79

Pineda et al. [66]

Cohort

36

MI

53.3

4

21

n/a

n/a

48.34

Wennberg et al. [67]

Case-Control

168

Healthy

25.83

n/a

469

n/a

n/a

25.11

Yano et al. [68]

Cohort

20

Smokers

64.57

n/a

11

n/a

55

36.54

Yano et al. [69]

Cohort

30

Hypertension

16.12

4

13

n/a

16

14.87

Knudsen et al. [70]

Case-Control

12

HIV

8.5

3

51

n/a

n/a

7

Golukhova et al. [71]

Cohort

28

Elective PCI

29.86

2

9

11

n/a

23.16